Product Description
Ketamine is used by medical practitioners and veterinarians as an anaesthetic. It's sometimes used illegally by people to get high.
Mechanisms of Action: NMDA Antagonist,Excitatory Amino Acid Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Egypt, Spain, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Bipolar Disorder|Colorectal Cancer|Depressive Disorder, Major|Digestive System Cancer|Gastrointestinal Cancer|Headache Disorders|Intestinal Diseases|Liver Cancer|Mouth Cancer|Mucositis|Oropharyngeal Cancer|Skin Cancer|Suicidality
Phase 2: Acute Pain|Cataract|Depressive Disorder, Treatment-Resistant|Healthy Volunteers|Methamphetamine Dependence|Stress Disorders, Post-Traumatic
Phase 1: Anorexia|Depressive Disorder|Morphine Dependence|Pain, Postoperative|Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| KetaMet | P2 |
Not yet recruiting |
Methamphetamine Dependence |
2025-11-01 |
|
| KetHead | P3 |
Recruiting |
Headache Disorders |
2025-10-01 |
|
| SevereBD | P3 |
Active, not recruiting |
Suicidality|Bipolar Disorder |
2024-12-31 |
95% |
| Ketamine Trial for Acute suicidality (KETA) | P2 |
Active, not recruiting |
Suicidality |
2024-06-08 |